Cytokinetics Inc (CYTK)
Profitability ratios
Return on sales
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | -890.46% | -2,872.48% | -2,886.73% | -4,547.97% | -3,239.73% | -3,996.80% | -2,918.16% | -179.75% | -154.59% | -41.19% | -29.01% | -168.06% | -127.09% | -575.92% | -110.08% | -82.36% | -73.66% | -58.44% | -339.34% | -279.32% |
| Operating profit margin | -2,902.72% | -16,297.79% | -16,148.37% | -13,272.04% | -6,589.71% | -6,344.43% | -4,843.18% | -378.18% | -342.75% | -147.66% | -118.84% | -343.79% | -264.54% | -932.79% | -219.08% | -177.95% | -168.27% | -149.57% | -590.60% | -471.06% |
| Pretax margin | -3,191.11% | -17,906.24% | -17,398.82% | -14,141.74% | -6,988.63% | -6,739.96% | -5,422.19% | -439.35% | -411.21% | -190.34% | -142.85% | -396.22% | -305.72% | -1,061.13% | -269.48% | -230.55% | -228.00% | -209.88% | -751.39% | -592.61% |
| Net profit margin | -3,191.11% | -17,906.24% | -17,398.82% | -14,141.74% | -6,964.09% | -6,640.58% | -5,684.47% | -475.10% | -462.47% | -227.04% | -156.43% | -414.04% | -305.72% | -1,061.13% | -269.48% | -230.55% | -228.00% | -209.88% | -751.39% | -592.61% |
The profitability ratios of Cytokinetics Inc, as indicated by the provided data, show consistent negative trends across various periods.
1. Gross Profit Margin: The gross profit margin has been highly negative, ranging from -29.01% to -4,547.97% over the periods analyzed. This indicates that the company is facing significant challenges in generating profits after accounting for the cost of goods sold.
2. Operating Profit Margin: The operating profit margin also shows a consistent pattern of negative values, varying from -118.84% to -16,297.79%. This implies that the company is incurring substantial operating expenses that are exceeding its revenue, leading to operating losses.
3. Pretax Margin: The pretax margin reflects the company's profitability before accounting for taxes, and it also displays negative values throughout the periods, ranging from -142.85% to -17,906.24%. This suggests that Cytokinetics Inc is experiencing losses at the pre-tax level.
4. Net Profit Margin: The net profit margin, which represents the profitability after all expenses, including taxes, remains consistently negative, with figures ranging from -156.43% to -17,906.24%. This indicates that the company is unable to achieve profitability even after considering all costs.
Overall, the trend of negative profitability ratios across all levels - gross, operating, pre-tax, and net profit margins - highlights the challenging financial situation of Cytokinetics Inc, indicating that the company is struggling to generate profits and is facing significant financial difficulties.
Return on investment
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | -38.26% | -36.53% | -33.21% | -61.62% | -60.20% | -66.95% | -61.80% | -41.67% | -31.95% | -20.34% | -23.28% | -26.11% | -22.15% | -24.29% | -22.44% | -18.06% | -17.60% | -17.14% | -47.46% | -40.81% |
| Return on assets (ROA) | -42.06% | -40.14% | -35.78% | -65.66% | -63.62% | -70.07% | -72.54% | -52.35% | -43.11% | -31.28% | -30.64% | -31.44% | -25.59% | -27.63% | -27.60% | -23.39% | -23.85% | -24.04% | -60.39% | -51.34% |
| Return on total capital | — | — | -435.37% | — | — | — | — | — | — | — | -167.49% | -198.87% | -78.48% | -81.75% | -752.07% | -147.94% | -79.11% | -52.01% | — | — |
| Return on equity (ROE) | — | — | -502.33% | — | — | — | — | — | — | — | -212.23% | -231.58% | -88.29% | -91.83% | -944.65% | -198.96% | -112.27% | -76.20% | — | — |
Based on the provided data, let's analyze Cytokinetics Inc's profitability ratios:
1. Operating Return on Assets (Operating ROA):
The Operating ROA reflects the company's ability to generate operating profits from its assets. Cytokinetics Inc's Operating ROA has been consistently negative over the reported periods, indicating that the company is not efficiently utilizing its assets to generate operating income. The decline in the Operating ROA from -40.81% in March 2020 to -38.26% in December 2024 shows a persistent challenge in improving operational efficiency.
2. Return on Assets (ROA):
ROA measures the company's overall ability to generate profit from its assets. Cytokinetics Inc's ROA has also been negative throughout the reported periods, indicating that the company is facing challenges in generating profits relative to its total assets. The decline in ROA from -51.34% in March 2020 to -42.06% in December 2024 reflects a struggle to improve profitability levels.
3. Return on Total Capital:
The Return on Total Capital represents the company's ability to generate returns for both equity and debt holders. Cytokinetics Inc's Return on Total Capital has fluctuated and remained negative, except for a few periods where data is not available. The negative values indicate that the company is not effectively utilizing its total capital to generate returns for its stakeholders.
4. Return on Equity (ROE):
ROE measures the company's profitability relative to shareholder's equity. Cytokinetics Inc's ROE has been consistently negative, indicating that the company is not generating sufficient returns for its equity holders. The downward trend in ROE from -76.20% in September 2020 to -502.33% in June 2024 highlights the challenges faced by the company in creating value for its shareholders.
In conclusion, the analysis of profitability ratios for Cytokinetics Inc reveals a persistent struggle in generating profits from its assets and capital. The negative values across all ratios suggest a need for the company to improve operational efficiency and profitability in order to enhance shareholder value and financial performance.